Can a common drug shield the brain from cancer treatment damage?
NCT ID NCT06649851
Summary
This study is testing if a drug called G-CSF (Filgrastim) can help protect the brain and preserve thinking skills in people with a specific type of brain cancer (MGMT-methylated glioblastoma) while they receive standard radiation and chemotherapy. Researchers want to see if adding G-CSF to the usual treatment can reduce the negative effects on brain structure and cognitive function. About 60 adults with newly diagnosed cancer will be randomly assigned to receive either standard care alone or standard care plus G-CSF.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MGMT-METHYLATED GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.